<DOC>
	<DOCNO>NCT01082146</DOCNO>
	<brief_summary>This open-label , non-randomized , absorption , metabolism , excretion study Lurasidone administer suspension 40 mg 6 normal healthy male subject postprandial state</brief_summary>
	<brief_title>RI-AME Study OF ISOTHIAZOLYL-3-14C-LURASIDONE</brief_title>
	<detailed_description>A Phase 1 Study Investigate Absorption , Metabolism , Excretion [ Isothiazolyl-3-14C ] -Lurasidone Following Postprandial Single Oral Dose Administration Healthy Male Subjects .</detailed_description>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>1. within BMI range 18.0 28.0 kg/m2 inclusive ; 2. male either sterile agree use Checkin 45 day follow Study Completion/Discharge approve method contraception 3. able comprehend willing sign Informed Consent Form ( ICF ) ; 4. able void urine daily basis 1 2 bowel movement per day . 5. able swallow 60 mL dose suspension . 1. history presence abnormal ECG 2. participation 1 radiolabeled investigational study drug trial within 12 month prior Checkin . 3. exposure significant radiation within 12 month prior Checkin ; 4. participation investigational study drug trial 5. use prescription medications/products within 14 day prior Checkin 6. use inhibitor inducer CYP3A4 take within 30 day prior Checkin , include limited drug list Appendix E ; 7. receipt blood product within 2 month prior Checkin ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>pharmacokinetics , lurasidone</keyword>
</DOC>